QuidelOrtho acquires TTP spin-out LEX Diagnostics to expand rapid point-of-care PCR portfolio

Grafa
QuidelOrtho acquires TTP spin-out LEX Diagnostics to expand rapid point-of-care PCR portfolio
QuidelOrtho acquires TTP spin-out LEX Diagnostics to expand rapid point-of-care PCR portfolio
Mahathir Bayena
Written by Mahathir Bayena
Share

QuidelOrtho (NASDAQ:QDEL), a global powerhouse in in vitro diagnostics, has announced the acquisition of LEX Diagnostics.

A spin-out from the UK-based TTP Group, LEX Diagnostics is at the forefront of ultra-fast molecular testing, bridging the gap between the speed of rapid antigen tests and the accuracy of laboratory-grade PCR.

LEX Diagnostics was founded in 2020 through a TTP innovation program designed to commercialize breakthroughs in thermal control.

The company’s core technology enables "ultra-fast thermal cycling," allowing clinicians to achieve high-sensitivity molecular results in a fraction of the time required by traditional PCR machines.

The acquisition follows a major regulatory milestone for LEX Diagnostics.

In February 2026, the company received U.S. Food and Drug Administration (FDA) 510(k) clearance and CLIA-waived status for its flagship VELO system.

The VELO platform is designed to detect Flu A, Flu B, and COVID-19 directly from a swab sample.

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.